| 000 | 01481 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250515034510.0 | ||
| 264 | 0 | _c20070202 | |
| 008 | 200702s 0 0 eng d | ||
| 022 | _a0885-3185 | ||
| 024 | 7 |
_a10.1002/mds.20936 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFox, Susan H | |
| 245 | 0 | 0 |
_aTranslation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cOct 2006 |
||
| 300 |
_a1578-94 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aBasal Ganglia _xdrug effects |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aDrugs, Investigational _xtherapeutic use |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xdrug therapy |
| 650 | 0 | 4 | _aHaplorhini |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aLang, Anthony E | |
| 700 | 1 | _aBrotchie, Jonathan M | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 21 _gno. 10 _gp. 1578-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.20936 _zAvailable from publisher's website |
| 999 |
_c16463779 _d16463779 |
||